CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative

CV Sciences, Inc.

Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.
Operating loss widened to $0.3M from $0.1M; adjusted EBITDA turned negative at -$0.1M vs +$0.1M.
Cash balance $0.3M; operating expenses cut 11.3% YoY to $1.7M.
44% of net revenue from new products launched since Jan 2023; 52 new products launched; launched PlusHLTH.com e-commerce.
U.S. Senate voted 61-32 on H.R. 6500 delaying restrictive hemp-derived cannabinoid provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.